The Epstein-Barr virus and a high-risk gene may work together to trick the immune system into attacking the brain in MS, a ...
Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...
NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating ...
ULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients ...
(Barcelona, Spain, Thursday, 25 September 2025) New research presented today at the 41 st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) reveals ...
TG Therapeutics will present data on BRIUMVI for relapsing multiple sclerosis at the ACTRIMS forum, February 27 – March 1, 2025. TG Therapeutics, Inc. announced the schedule for presentations on data ...
Multiple sclerosis (MS) is characterized by a broad array of symptoms. Despite this variability, most individuals with MS will exhibit a distinct set of symptoms during their initial clinical attack.
TG Therapeutics, Inc. announced that it will present data on its multiple sclerosis treatment BRIUMVI® (ublituximab-xiiy) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback